Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. filed an initial ownership report for its CFO / CLO, Nassif David W., detailing his current equity position in the company. He directly holds 123,925 shares of common stock and several stock option grants over Pharvaris shares.
These options cover 60,000 shares at $28.00 per share expiring in 2036, 60,000 shares at $16.05 expiring in 2035, 75,000 shares at $15.94 expiring in 2034, and 230,000 shares at $20.15 also expiring in 2034. The common share holdings include restricted stock units that vest over time, such as a 20,000-unit award granted in March 2026 with 25% vesting in March 2027 and the remainder vesting monthly.
Pharvaris N.V. executive Stefan Andreas Abele, Chief Technical Ops Officer, reports his initial equity holdings. He holds several stock option awards over common shares, including options exercisable at $28.0000, $16.0500, $22.3100 and $16.4000, with expiration dates between November 15, 2033 and March 3, 2036. These options cover 60,000, 60,000, 40,000 and 89,500 underlying common shares, respectively. He also reports direct ownership of 43,942 shares of common stock as of March 18, 2026, which includes restricted stock units granted under the company’s equity plan that vest over time according to the schedules described in the footnotes.
Pharvaris N.V. executive Dr. Anne Lesage, Chief Early Development, filed an initial Form 3 reporting her ownership in the company. She lists multiple stock option awards on common stock, including grants covering 60,000 shares at an exercise price of $28.0000 expiring on March 3, 2036 and other options with exercise prices ranging from $2.5900 to $22.3100. She also reports Common Stock holdings of 56,450 shares directly and 163,969 shares indirectly through GrayMatters Consulting B.V. Footnotes note outstanding restricted stock units from prior awards that settle in common shares with time-based vesting schedules.
Pharvaris N.V. Chief Commercial Officer Wim Souverijns filed a Form 3 reporting his initial equity holdings in the company. As of March 18, 2026, he holds 55,111 shares of common stock directly, including restricted stock units that settle in common shares.
He also reports multiple stock option awards on common stock, such as 55,000 underlying shares at an exercise price of 28.0000 per share expiring on March 3, 2036, and 75,000 underlying shares at 8.0500 per share expiring on April 6, 2033. Footnotes describe time-based vesting schedules, typically with 25% vesting on a specified date and the remainder vesting in equal monthly installments over 48 months.
Pharvaris N.V. Principal Accounting Officer Anna Nijdam filed an initial ownership report showing her equity stake in the company. She holds 51,819 shares of common stock directly, along with a stock option on 30,000 shares of common stock at an exercise price of $20.00 per share that expires on February 5, 2031. The option vested 25% on February 5, 2022, with the remaining shares vesting in equal monthly installments thereafter. The filing also notes multiple outstanding restricted stock unit awards that settle in common shares, each vesting 25% on the first vesting date and 25% on each annual anniversary.
Pharvaris N.V. director David P. Meeker reports his current equity holdings, including common shares, stock options and restricted stock units. He holds 65,167 shares of Common Stock directly, as well as multiple stock option awards to buy additional shares at exercise prices ranging from $7.89 to $28.00 per share, with expirations between 2031 and 2036. The filing also notes outstanding restricted stock units, including 5,500 RSUs from an award granted on March 3, 2026 that will fully vest on March 3, 2027, settling in common stock.
Pharvaris N.V. director Viviane Monges has filed an initial statement of beneficial ownership detailing her equity position in the company. The filing lists several stock option awards on common stock with exercise prices between 8.0500 and 28.0000 per share and expiration dates running through 2036. It also shows direct ownership of 14,654 shares of common stock and notes restricted stock units granted under the company’s equity plan, including 5,500 RSUs from an award granted March 3, 2026 that will fully vest on March 3, 2027.
Pharvaris N.V. Chief Medical Officer Lu Peng reported her initial ownership in a Form 3 filing. She directly holds 66,309 shares of common stock as of March 18, 2026, which includes restricted stock units that settle in common shares.
She also holds multiple stock option awards on common stock with various exercise prices and long-dated expirations. These include options covering 245,308 shares at an exercise price of $2.59 per share expiring in 2030, and additional grants at higher exercise prices expiring between 2031 and 2036. Many of these options and RSUs vest 25% on a specified date, with the remaining portion vesting in equal monthly installments over four years.
Pharvaris N.V. director and Chief Executive Officer Berndt Modig filed an initial ownership report showing his equity position in the company. He directly holds 165,417 shares of common stock, plus additional restricted stock units that vest over time. He also has indirect ownership of 950,000 common shares through Schoodic Management B.V., an entity he controls. In addition, he holds multiple stock option awards on common shares with exercise prices ranging from $8.05 to $28.00 and expiration dates between 2031 and 2036, providing long-dated upside exposure tied to the company’s share price.
Pharvaris N.V. executive Annick Deschoolmeester, Chief Human Resources Officer, has filed an initial ownership report showing her equity interests in the company. She directly holds 92,553 shares of common stock, which include restricted stock units that vest over several years under prior equity awards.
She also holds stock options over additional Pharvaris common shares, including 60,000 options at $28.00 per share expiring on March 3, 2036, 60,000 options at $16.05 expiring on April 12, 2035, 45,000 options at $22.31 expiring on April 11, 2034, and 70,000 options at $8.05 expiring on April 6, 2033. These options and RSUs vest gradually, with portions vesting on specific dates and the remainder in monthly installments or annual tranches.